

#virus

Data Science High Frequency Indicators Update Maybe Too Soon


Even before the effects of official reopening policies can be seen in the data, our model of the relationship between social distancing and COVID-19 case growth suggests that US case growth could swing back into positive territory. And there is room for reopening to accelerate that swing if social interactions increase.

Revisiting our model of the relationship between foot traffic in public places and COVID-19 growth suggests that social distancing has already decreased enough since mid-April to swing national case growth from slightly negative to slightly positive. If reopening policies increase traffic, and there are not enough reductions from mask use and a higher share of interactions happening outdoors, we could see growth pick up (which could in turn result in renewed social distancing policies).

In our other high frequency data, New York City hospital visits are now at record lows for the history available, suggesting that its time as the epicenter of COVID-19 is now behind it. Jobless claims appear poised to decline, but remain in the territory of several million, showing continued economic stress. And while we continue to see declines in information-seeking series like visits to the CDC website, we are not yet seeing a meaningful revival in air travel or staffing in S&P 500 HQs. Next week will likely be the first where datapoints reflect reopening policies now rolling out, so that may change.

FIGURE 1

Road Traffic Has Increased from Trough Levels in All States, but More Than Half Of States Are Still Experiencing Positive Growth in New COVID-19 Cases



Source: NYC Open Data, State Government Websites, Barclays Research

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA.

This is a Special Report that is not an equity or a debt research report under U.S. FINRA Rules 2241-

FOR ANALYST CERTIFICATION(S) PLEASE SEE PAGE 12.

FOR IMPORTANT FIXED INCOME RESEARCH DISCLOSURES, PLEASE SEE PAGE 12.

FOR IMPORTANT EQUITY RESEARCH DISCLOSURES, PLEASE SEE PAGE 13.

Special Report | Research

6 May 2020

Investment Sciences

Investment Sciences

Ryan Preclaw +1 212 412 2249

ryan.preclaw@barclays.com BCI. US

Ben McSkelly, CFA +44 (0)20 3555 3606 ben.mcskelly@barclays.com Barclays, UK

Troy Li +1 212 526 1825 troy.li@barclays.com BCI, US

Data Science

Adam Kelleher ** +1 212 526 5697 adam.kelleher@barclays.com BCI. US

Xuyan Xiao ** +1 212 526 8487 xuyan.xiao@barclays.com BCI, US


^{**}This author is a member of the Fixed Income. Currencies and Commodities Research department and is not an equity or debt research analyst.

The Retreat of Social Distancing May Have Arrived Too Soon

The majority of recent headlines about COVID-19 have been focused on the arrival of relaxation in social distancing, with rules being relaxed at least slightly in many states starting at the beginning of May.¹

But even before the official arrival of less strict policies, data suggested that distancing was retreating in many placed. According to TomTom, the y/y change in US road traffic rose by about 10pp from the beginning of April to the beginning of May (Figure 2). Similarly, our measure of foot traffic in more than 2mn public places increased after the middle of April.


FIGURE 2
Road Traffic Volumes Increased About 10pp in April



Source: TomTom, Barclays Research

FIGURE 3

Public Place Foot Traffic Also Increased After Mid-April




Source: Complementics, Pitney Bowes, Barclays Research

Unfortunately, the increase of social contact is only loosely aligned to successful reduction in the growth of COVID-19 cases. Across the US, we see a similar increase in traffic between places that have negative and positive case growth (Figure 4).

FIGURE 4

Road Traffic Has Rebounded in States With Both Negative and Positive COVID-19 New Case Growth




Source: TomTom, The COVID Tracking Project

¹ Relaxed Rules and Warm Weather Test States, New York Times, May 2, 2020

In April, we published a model that suggested social distancing as measured by traffic in public places had a clear relationship with COVID-19 case growth (*Social Distancing Is Almost Everywhere*, and *Working...Slowly*, April 13, 2020). Although this relationship should change if COVID-19 infections reach a level where herd immunity is more meaningful (from "finite population effects"), the relationship appears to be stable for the moment (Figure 5).

FIGURE 5
Less Foot Traffic in Public Places has Coincided with Slower Growth in COVID-19 Cases



Source: Complementics, Pitney Bowes, The COVID Tracking Project, Barclays Research

In mid-April, the relationship suggested that there was enough social distancing to make case growth negative in almost every state, but that differences in when distancing took effect would mean that as early-distancing states like New York saw case growth decline, later-starting states would add enough new cases to partially offset gains. The data suggest that something very much like that has happened so far (Figures 6 and 7).

FIGURE 6
Case Growth Has Declined in New York...





FIGURE 7

...But Continued to Rise Modestly in the Rest of the US



Source: The COVID Tracking Project, Barclays Research


Source: Johns Hopkins, The COVID Tracking Project, Barclays Research

Although it saw a slower decline in cases than we might have hoped, our mid-April model suggested that growth would decline steadily. Revisiting that model today suggests a different path: even the modest (and mostly unofficial) loosening of social distancing in data through beginning of May might already be enough to push US national case growth positive (Figure 8). And if reopening in many places reduces distancing even more, that

path could end up being worse. That could, in turn, then require another round of tightened distancing rules (and increased economic risk) in the medium term.

FIGURE 8

The Recent Decline in Social Distancing Already Implies a Potential Acceleration in New Cases, Even Before the Effect of Relaxed Distancing Rules Appear in the Data



Source: Complementics, Pitney Bowes, The COVID Tracking Project, Barclays Research

Of course, these dynamics could change for other reasons. There is evidence from Taiwan that universal mask use could reduce transmission by 90%+.2 It may be that if most of the increase is social interactions happens outdoors, there will be a lower risk of transmission because of more space and more sunlight.³ That said, we have not seen those effects clearly help with case growth data yet, so it seems risky to depend on them until we see them actually produce results.

² Virus Outbreak: Masks greatly limit spread: CECC, Taipei Times, May 4, 2020

³ The case for reopening America's parks, Vox, April 30, 2020

High Frequency Series Updates

Tracking COVID-19 Confirmed Cases

There were 23,976 confirmed new cases of COVID-19 in the US yesterday, an increase of 1,641 from 22,335 new cases the day before. The cumulative total cases grew to 1,204,351 from 1,180,375 the day before. The 3-day trailing daily CDGR in cumulative cases was 2%.

There were 258,992 new tests administered for COVID-19 in the US yesterday, an increase of 27,201 from 231,791 new tests the day before. The positive test rate was 9%, down from 10% the day before.

FIGURE 9

Growth in New Total Tests

100%

75%

50%

25%

0%


12-Mar 22-Mar 01-Apr 11-Apr 21-Apr 01-May

New Test Tr. 3-Day CDGR

Source: the COVID Tracking Project, Barclays Research

FIGURE 11

7d Trailing Average of New US Confirmed Cases



Source: Johns Hopkins, Barclays Research


FIGURE 10



Source: Johns Hopkins, the COVID Tracking Project, Barclays Research

FIGURE 12

US Daily Growth in New Cases




Note: Chart since the US crossed the 100-case threshold. Source: Johns Hopkins, Barclays Research

New York City Hospital Emergency Room Admissions

In New York City, the number of emergency room visits has now completed a full swing. Not only has it declined sharply from record highs, but on the most recent day reported, May 2nd, the number of combined visits for respiratory and influenza-like and respiratory illnesses fell to the *lowest* since at least 2015 (the earliest day data is available in the system).

FIGURE 13

NYC Hospital Emergency Room Visits for Combined Flu-like and Respiratory Illnesses Fell to the Lowest on Record



Source: New York City Department of Health, Barclays Research


For details about how we look at emergency room admissions, see *Data Science High Frequency Indicators: NYC Emergency Room Admissions Are Already at Peaks*, March 16, 2020.

Jobless Claims

NYC 311 calls about unemployment have been quite useful in anticipating the jump in national initial jobless claims filings released every Thursday. After declining for most of April, 311 unemployment calls increased for the second week in a row. Other states' early claim filings are mixed, but averaging across sources suggests a further decline in jobless claims, but only to a level that remains in the multiple millions. Bloomberg is reporting a median Wall Street estimate of a drop to 3mn claims, which seems roughly in line with what is implied by high frequency sources.

FIGURE 14

The Jobless Claim Picture is Mixed Again, but is Consistent With a Further Decline in New Claims, Though Still Only to Levels That Imply Extreme Economic Stress



Source: NYC Open Data, State Government Websites, Barclays Research


For details about how we look at the relationship between 311 unemployment calls and initial jobless claims, see *311 Calls About Unemployment Lead Weekly Jobless Claims*, March 24, 2020.

Road Traffic

Road traffic data are reported by TomTom for more than 400 cities globally and are one of the rare high frequency indicators that can be applied equally to many countries. Here, the past week has finally shown clear signals of increased activity across each of the US, Europe, and China, though May and Labor Day holidays in many countries added some noise to the data.

FIGURE 15

Road Traffic is Now Rising Distinctly in the US, Europe, and China (Distortions from May Day Holidays Not Withstanding)



Source: TomTom, Barclays Research


For details about how we look at road traffic, see *Data Science High Frequency Indicators: TomTom congestion data show impact of global lockdowns*, April 9, 2020.

Airports

Nationally, airport traffic remains higher than the recent trough, but is extremely suppressed relative to normal.

FIGURE 16

Traffic at Airports across the US Remain Off Troughs, but Deeply Suppressed



Source: Complementics, Barclays Research

For details about how we look at airport traffic, see *Data Science High Frequency Indicators: US Airport Traffic Is Down and Falling*, March 12, 2020.

NYC Subways

Subway ridership appears to remain at the now-flattened steady rate of down >90% (Figure 10-11).

For details about how we look at subway ridership, see *Data Science High Frequency Indicators: NYC Subway Ridership Is Declining*, March 10, 2020.

S&P 500 Headquarters

S&P 500 company headquarters staffing remains near zero. The median company has reduced headquarters staffing by almost 95%, which has now been essentially steady for several weeks.




NYC Subway Ridership Remains Near Zero...



Source: MTA, Barclays Research

FIGURE 18


...Whether Measured Daily or Weekly



Source: MTA, Barclays Research

FIGURE 19

S&P 500 Company HQ Staffing Is Holding Steady at Very Reduced Levels



Source: Complementics, Barclays Research

And 80% of S&P 500 constituents have cut staffing by more than 80% (Figure 15), a figure that has been constant for several weeks.

FIGURE 20

More Than 80% of S&P 500 Companies Have Reduced Headquarters Staff by 80% or More, Essentially Unchanged from Last Week



Source: Complementics, Barclays Research


For details about how we look at S&P HQ staffing, see *Data Science High Frequency Indicators: S&P Companies Have Committed to Social Distancing*, March 16, 2020.

NYC 311 Calls for COVID-19 Information

311 calls for COVID-19 information are touching lower peaks, and lower troughs, suggesting waning attention in the city.

FIGURE 21

NYC 311 Calls Seeking Information about COVID-19 Are Waning



Source: NYC Open Data, Barclays Research


For details about how we look at 311 call volume, see *Data Science High Frequency Indicators: COVID-19 Calls to NYC's 311 Are Starting to Spike*, March 13, 2020.

Visits to the CDC Website

Visits to the CDC website have continued their declines off mid-March peaks (Figure 17).

FIGURE 22

Visits to CDC Website Have Now Sustained a Multi-week Decline from Their Peak



Source: analytics.usa.gov, Barclays Research


For details of how we look at CDC website traffic, see *Data Science High Frequency Indicators: Visits to CDC Websites Have Spiked*, March 16, 2020.

Twitter

Tweets that are "virus" or "Covid" related have remained quite stable for several weeks with slight downward sloping. They remain about 50% of peaks, suggesting that the virus continues to be a topic of online conversations.

FIGURE 23

Population Normalized Count of "Virus" or "COVID" Related Tweets, by Country



Source: Twitter, United Nations, Barclays Research

For details about how we look at tweet volume, see *Data Science High Frequency Indicators: COVID-19 Tweet Surges Vary by Country*, March 16, 2020.

ANALYST(S) CERTIFICATION(S):

We, Ryan Preclaw, Ben McSkelly, CFA and Adam Kelleher, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

FICC: IMPORTANT DISCLOSURES

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays").

All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

For current important disclosures regarding any issuers which are the subject of this research report please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that Barclays may have a conflict of interest that could affect the objectivity of this report. Barclays Capital Inc. and/or one of its affiliates regularly trades, generally deals as principal and generally provides liquidity (as market maker or otherwise) in the debt securities that are the subject of this research report (and related derivatives thereof). Barclays trading desks may have either a long and / or short position in such securities, other financial instruments and / or derivatives, which may pose a conflict with the interests of investing customers. Where permitted and subject to appropriate information barrier restrictions, Barclays fixed income research analysts regularly interact with its trading desk personnel regarding current market conditions and prices. Barclays fixed income research analysts receive compensation based on various factors including, but not limited to, the quality of their work, the overall performance of the firm (including the profitability of the Investment Banking Department), the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst. To the extent that any historical pricing information was obtained from Barclays trading desks, the firm makes no representation that it is accurate or complete. All levels, prices and spreads are historical and do not necessarily represent current market levels, prices or spreads, some or all of which may have changed since the publication of this document. Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations and trade ideas contained in one type of Barclays Research may differ from those contained in other type

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://publicresearch.barcap.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://publicresearch.barcap.com/S/CM.htm.

All pricing information is indicative only. Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

Types of investment recommendations produced by Barclays FICC Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts in FICC Research. Any such investment recommendations produced by non-Credit Research teams shall remain open until they are subsequently amended, rebalanced or closed in a future research report. Any such investment recommendations produced by the Credit Research teams are valid at current market conditions and may not be otherwise relied upon.

Disclosure of other investment recommendations produced by Barclays FICC Research:

Barclays FICC Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays FICC Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

FICC: IMPORTANT DISCLOSURES CONTINUED

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore) Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

EQUITY: IMPORTANT DISCLOSURES

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

Availability of Disclosures:

Where any companies are the subject of this research report, for current important disclosures regarding those companies please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities, the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst.

Research analysts employed outside the US by affiliates of Barclays Capital Inc. are not registered/qualified as research analysts with FINRA. Such non-US research analysts may not be associated persons of Barclays Capital Inc., which is a FINRA member, and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst's account.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.

Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://publicresearch.barcap.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://publicresearch.barcap.com/S/CM.htm.

Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

Guide to the Barclays Fundamental Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").

In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

Stock Rating

Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Rating Suspended - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is acting in an advisory capacity in a merger or strategic transaction involving the company.

Industry View

Positive - industry coverage universe fundamentals/valuations are improving.

Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

Negative - industry coverage universe fundamentals/valuations are deteriorating.

EQUITY: IMPORTANT DISCLOSURES CONTINUED

Distribution of Ratings:

Barclays Equity Research has 1565 companies under coverage.

44% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 49% of companies with this rating are investment banking clients of the Firm; 74% of the issuers with this rating have received financial services from the Firm.

38% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 43% of companies with this rating are investment banking clients of the Firm; 68% of the issuers with this rating have received financial services from the Firm.

15% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 32% of companies with this rating are investment banking clients of the Firm; 61% of the issuers with this rating have received financial services from the Firm.

Guide to the Barclays Research Price Target:

Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's price target over the same 12-month period.

Top Picks:

Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant "industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each industry. To view the current list of Top Picks, go to the Top Picks page on Barclays Live (https://live.barcap.com/go/keyword/TopPicks).

To see a list of companies that comprise a particular industry coverage universe, please go to https://publicresearch.barclays.com.

Types of investment recommendations produced by Barclays Equity Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.

Disclosure of other investment recommendations produced by Barclays Equity Research:

Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

Barclays Bank PLC, DIFC Branch (Barclays Bank, DIFC)

Disclaimer:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research reports should contact debtresearch@barclays.com. Clients that are subscribed to receive equity research reports, will not receive certain cross asset research reports co-authored by equity and FICC research analysts that are distributed as "institutional debt research reports" unless they have agreed to accept such reports. Eligible clients may get access to such cross asset reports by contacting debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area ("EEA"): This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A. This material is distributed in the Cayman Islands and in the Bahamas by Barclays Capital Inc., which it is not licensed or registered to conduct and does not conduct business in, from or within those jurisdictions and has

not filed this material with any regulatory body in those jurisdictions.

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INB100000950). Barclays Investments and Loans (India) Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC or one of the Barclays group entities. None of Barclays Bank PLC, nor such Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001. This material is distributed in New Zealand by Barclays Bank PLC, but it has not been registered, filed or approved by any New Zealand regulatory authority or under or in accordance with the Financial Markets Conduct Act of 2013, and this material is not a disclosure document under New Zealand law.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). This material does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe for or purchase, any securities or investment products in the UAE (including the Dubai International Financial Centre) and accordingly should not be construed as such. Furthermore, this information is being made available on the basis that the recipient acknowledges and understands that the entities and securities to which it may relate have not been approved, licensed by or registered with the UAE Central Bank, the Dubai Financial Services Authority or any other relevant licensing authority or governmental agency in the UAE. The content of this report has not been approved by or filed with the UAE Central Bank or Dubai Financial Services Authority. Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2020). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14

5HP. Additional information regarding this publication will be furnished upon request.